HEALTHCARE & REMOTE PATIENT MONITORING
RESP® Biosensor
Manage lung health from hospital to home with objective, real-time monitoring of symptoms
FDA 510(k) Class II Device | CE Mark | HIPAA Compliant
Technology Overview
Developed by an asthma patient, the RESP® Biosensor offers clinicians a new approach to manage chronic respiratory diseases and break the cycle of readmissions for at-risk patients.
- Continuous lung sound monitoring: wearable device passively captures adventitious lung sounds such as cough, wheeze and crackles.
- Patient-friendly device: Wireless, discreet design that respects patient comfort and lifestyle.
- Earlier notice of exacerbations: Allows clinicians to remotely detect early signs of deterioration and adjust treatment plans.
Track Patient Progress Objectively and Remotely
KEY FEATURES
- Passive & continuous
- Wireless & lightweight
- HIPAA compliant
- Reimbursable under RTM & RPM codes
- 24+ hour battery life
- Rechargeable
- EHR/telehealth integration
- Proprietary machine learning algorithms* for event detection
*Machine learning algorithms not FDA cleared
The Strados Difference
LUNG ACOUSTICS
The primary distinction between our device and standard of care is our ability to extend the range of the stethoscope. Abnormal lung sounds such as cough, wheeze, rhonchi, and crackles can indicate various respiratory issues, including airway obstruction, fluid accumulation, or inflammation. These sounds often offer the earliest signs of respiratory distress or disease exacerbation.
Addressing Gaps in Traditional Standard of Care
Pulmonary Function Tests
- Episodic
- Patient-effort dependent
- Not used to predict exacerbations
Patient E-Diaries
- Prone to inconsistency
- Limited clinical utility
- Relies on patient effort and recall
Pulse Oximetry
- Limited insight into respiratory system
- Less sensitive in detecting early, sudden changes
RESP® Biosensor
- Objective and continuous
- Comprehensive respiratory data
- Enables earlier detection of exacerbations
Clinical Evidence
The value and clinical validation of the RESP Biosensor has been presented at several respiratory conferences including the American Thoracic Society and CHEST.
RESP® Biosensor Care Settings and Applications
Ambulatory Care
- Remote monitoring of at-risk COPD & Asthma patients
- Interstitial lung diseases
- Heart failure
- Pulmonary Rehabilitation
Acute Care
- In-patient status monitoring
- Chronic, complex care management
- Hospital at Home
- Tele-ICUs
Post-Acute Care
- Post-discharge hospital to home
- Post-surgical recovery and rehabilitation
- Skilled-nursing and long-term care facilities
Patient Journey Example
Patient is prescribed RESP® Biosensor for two weeks
On day 5, clinician receives alert of increased coughing and wheezing
Clinician checks in with patient virtually and adjusts treatment plan to avoid a readmission
OVERVIEW VIDEO
“With this information we can predict if the patient is doing better or worse and intervene ahead of time to prevent the patient having major complications”
– Sadia Benzaquen, MD, Chair of Pulmonary Critical Care, Einstein Medical Center